Alembic Pharmaceuticals Q2 Results
- BSE: 533573
- NSE: APLLTD
- ISIN: INE901L01018
- Sector: Biotechnology & Drugs
BSE
949.85
-27.40 (-2.80%)
-27.40 (-2.80%)Volume6.95 K
Updated: Fri 24 Jan, 2025 | 15:29:34
NSE
949.90-28.20 (-2.88%)
-28.20 (-2.88%)Volume3.88 L
Updated: Fri 24 Jan, 2025 | 15:47:08
Technical Trends
Long TermConsiders price movement over the last 6 months
Not Available
Short TermConsiders price movement over the last 1-2 weeks
Not Available
- Bearish
- Moderately Bearish
- Neutral
- Moderately Bullish
- Bullish
Insight: Trends unavailable at the moment.
Q2 Results Highlights
- Total Income₹1,647.98 Cr.(3.33%)
- Operating Profit₹181.62 Cr.(29.09%)
- Profit After Tax₹153.40 Cr.(12.33%)
- Operating Margin11.02%(24.94%)
Note: Comparison is on YoY basis
Quarterly - Alembic Pharmaceuticals Q2 Results
*All figures in crores except per share values
| Fiscal Period | Sep 24 | Jun 24 | QoQ Comp | Sep 23 | YoY Comp |
|---|---|---|---|---|---|
| Total Revenue | 1,647.98 | 1,561.73 | 5.52% | 1,594.93 | 3.33% |
| Selling/ General/ Admin Expenses Total | 391.47 | 379.77 | 3.08% | 346.99 | 12.82% |
| Depreciation/ Amortization | 70.51 | 69.04 | 2.13% | 67.56 | 4.37% |
| Other Operating Expenses Total | 588.13 | 551.04 | 6.73% | 578.26 | 1.71% |
| Total Operating Expense | 1,466.36 | 1,393.94 | 5.20% | 1,454.24 | 0.83% |
| Operating Income | 181.62 | 167.79 | 8.24% | 140.69 | 29.09% |
| Net Income Before Taxes | 180.42 | 157.03 | 14.90% | 134.64 | 34.00% |
| Net Income | 153.40 | 134.37 | 14.16% | 136.56 | 12.33% |
| Diluted Normalized EPS | 7.24 | 6.84 | 5.78% | 6.95 | 4.10% |